|本期目录/Table of Contents|

[1]王 旋,崔立春,党升强.阿帕替尼联合艾瑞卡对NSCLC患者免疫细胞表面分子表达的影响[J].中华肺部疾病杂志,2021,(05):554-558.[doi:10.3877/cma.j.issn.1674-6902.2021.05.002]
　Wang Xuan,Cui Lichun,Dang Shengqiang..Effect of apatinib and Erica on the expression of immune cell surface molecules in patients with NSCLC[J].,2021,(05):554-558.[doi:10.3877/cma.j.issn.1674-6902.2021.05.002]
点击复制

阿帕替尼联合艾瑞卡对NSCLC患者免疫细胞表面分子表达的影响(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年05期
页码:
554-558
栏目:
论著
出版日期:
2021-10-20

文章信息/Info

Title:
Effect of apatinib and Erica on the expression of immune cell surface molecules in patients with NSCLC
作者:
王 旋; 崔立春; 党升强
710016 西安,长安医院肿瘤科
Author(s):
Wang Xuan;  Cui Lichun;  Dang Shengqiang.
Department of Oncology, Changan Hospital, Xi'an 710016, China
关键词:
阿帕替尼;  艾瑞卡;  非小细胞肺癌;  CD39;  PD-1;  预后
Keywords:
Apatinib;  Erica;  Non-small cell lung cancer;  CD39;  PD-1;  Prognosis
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2021.05.002
摘要:
目的 分析阿帕替尼联合艾瑞卡对非小细胞肺癌患者免疫细胞表面分子表达的影响,并免疫细胞表面分子与临床预后的相关性。方法 采用巢式对照研究法,以确诊为晚期非小细胞肺癌为研究起点,将接受放化疗+阿帕替尼靶向治疗的病例作为阿帕替尼组35例,将与阿帕替尼组基线资料相匹配的接受放化疗+阿帕替尼+艾瑞卡的病例作为阿帕艾瑞组30例。观察阿帕替尼组和阿帕艾瑞组临床预后情况(总生存月数)及血清免疫指标(CD4+ T细胞、Treg细胞及表面分子CD39+、PD-1+)表达情况,并采用生存时间Kaplan-Meier曲线分析CD39、PD-1表达对临床预后的影响。结果 阿帕艾瑞组平均总生存时间(8.57±1.34)个月长于阿帕替尼组(6.70±0.54)个月,P<0.05。与治疗前比较,治疗后阿帕替尼组和阿帕艾瑞组的CD4+ CD39+、CD4+ PD-1+表达水平均下降,但阿帕艾瑞组的CD4+ CD39+、CD4+ PD-1+表达水平下降幅度高于阿帕替尼组(P<0.05)。与治疗前比较,治疗后阿帕替尼组和阿帕艾瑞组的Treg+CD39+、Treg+PD-1+表达水平均下降,但阿帕艾瑞组的Treg+CD39+、Treg+PD-1+表达水平下降幅度高于阿帕替尼组(P<0.05)。CD39阳性表达病例的平均总生存时间(5.48±0.34)个月短于CD39阴性表达病例(9.61±1.28)个月(P<0.05)。PD-1阳性表达病例的平均总生存时间(5.44±0.28)个月短于PD-1阴性表达病例(9.89±1.19)个月(P<0.05)。结论 与阿帕替尼辅助放化疗方案比较,阿帕替尼联合艾瑞卡辅助放化疗可获取到更佳总生存时间收益,可改善非小细胞肺癌患者免疫相关细胞CD39、PD-1蛋白的表达,可能与艾瑞卡的恢复机体抗肿瘤免疫力有关。
Abstract:
Objective To observe the effect of apatinib combined with Erica on the expression of immune cell surface molecules in patients with non-small cell lung cancer, and the correlation between immune cell surface molecules and clinical prognosis. Methods Using the nested control method, the patients with advanced non-small cell lung cancer were treated with radiotherapy and chemotherapy + apatinib targeted therapy as apatinib group(35 cases), and the patients with radiotherapy and chemotherapy + apatinib + Arica matched with the baseline data of apatinib group as apairib group(30 cases). The clinical prognosis(total survival months)and the expression of serum immune indexes(CD4+ T cells, Treg cells and surface molecules CD4+, PD-1)were observed in apatinib group and apairi group. The influence of CD39 and PD-1 expression on the clinical prognosis was analyzed by the survival time Kaplan Meier curve. Results The mean total survival time of apairi group(8.57±1.34)months was longer than that of apatinib group(6.70±0.54)months(P<0.05). Compared with that before treatment, the expression levels of CD4+ CD39+、CD4+ PD-1+ in apairinib group and apairinib group decreased after treatment, but the decrease of CD4+ CD39+, CD4+ PD-1+ in apairinib group was higher than that in apairinib group(P<0.05). Compared with that before treatment, Treg+CD39+, Treg+PD-1+ expression in apatinib group and apairib group decreased after treatment, but Treg+CD39+, Treg+PD-1+ expression in apairib group decreased more than that in apatinib group(P<0.05). The average total survival time of CD39 positive cases(5.48±0.34)months was shorter than that of CD39 negative cases(9.61±1.28)months(P<0.05). The mean total survival time of PD-1 positive cases(5.44±0.28)months was shorter than that of PD-1 negative cases(9.89±1.19)months(P<0.05). Conclusion Compared with apatinib adjuvant radiotherapy and chemotherapy, apatinib combined with Arica adjuvant radiotherapy and chemotherapy can obtain better total survival time benefits, improve the expression of CD39 and PD-1 protein in immune related cells of non-small cell lung cancer patients, which may be related to the recovery of anti-tumor immunity of Arica.

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 陈 正, 高 宁, 张 超, 等. 派姆单抗在非小细胞肺癌治疗中的研究进展[J]. 中国现代应用药学, 2019, 14(5): 639-643.
3 Siegel RL, Miller KD, Jemal A, et al. 2018 CA Cancer J Clin[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
4 Zukin M, Barrios CH, Pereira JR, et al. National Center for Health Statistics, CDC WONDER Online database, compiled from compressed mortality file[J]. Cancer immunology, 2018, 20(7): 384-388.
5 方 勇, 程 曦. 消化道恶性肿瘤抗血管生成靶向药物治疗的现状[J]. 浙江医学, 2019, 41(23): 2458-2465.
6 Sahyon HA, Alharbi SA. Chemoprotective role of an extract of the heart of the Phoenix dactylifera tree on adriamycin-induced cardiotoxicity and nephrotoxicity by regulating apoptosis, oxidative stress and PD-1 suppression[J]. Research Association, 2019, 13(51): 1084-1094.
7 白文粱, 刘 磊, 王桂阁, 等. PD-1/PD-L1抗体治疗晚期非小细胞肺癌研究进展[J]. 中国胸心血管外科临床杂志, 2019, 14(31): 1-7.
8 Faas MM, Saez T, de Vos P. Extracellular ATP and adenosine: The Yin and Yang in immune responses[J]. Mol AspectsMed, 2017, 55(11): 109-119.
9 陈达展, 周 成. EGFR-TKIs联合放疗对晚期非小细胞脑转移癌的疗效评价[J]. 吉林医学, 2019, 40(01): 75-78.
10 张亚年, 仲 宁, 张 璐, 等. 康艾注射液联合贝伐珠单抗和DP方案治疗非小细胞肺癌的临床研究[J]. 现代药物与临床, 2019, 34(12): 3690-3695.
11 王元艳, 杨 泽, 韦翔耀, 等. 非小细胞肺癌放疗抵抗相关因素研究进展[J]. 现代中西医结合杂志, 2019, 28(36): 4099-4101.
12 徐林友, 胡文锋. 甲磺酸阿帕替尼治疗非小细胞肺癌临床疗效及安全性分析[J]. 山西医药杂志, 2019, 48(24): 3095-3097.
13 Iderzorig T, Kellen J, Osude C, et al. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.Biochem[J]. Biophys Res, 2018, 18(2): 496-502.
14 Datta J, Strong VE. Less may be more: shifting paradigm toward minimally invasive gastrectomy for locally advanced gastric cancer[J]. Translational, 2019, 4(36): 2315-2319.
15 吕 璐, 肖 蓉. 重组人血管内皮抑素联合化疗治疗晚期消化道肿瘤的有效性及安全性的Meta分析[J]. 全科医学临床与教育, 2019, 17(6):4 88-493,507.
16 Han HB, Lee KE, Choi JH, et al. Functional dissociation of oscillations in the frontal and visual cortices and their long-range network during sustained attention.[J]. eNeuro, 2019, 6(6): 849-854.
17 周建红, 陈海辉, 黄海欣, 等. 阿帕替尼在晚期胃癌真实世界治疗中的疗效及安全性分析[J]. 现代肿瘤医学, 2019, 14(2): 264-267.
18 袁 茵, 宫 颢, 李永文, 等. 阿帕替尼对肺癌细胞侵袭迁移的影响及其作用机制[J]. 中国肺癌杂志, 2019, 22(5): 264-270.
19 尹 洁. NGAL、dNLR和LDH在卡瑞利珠单抗联合甲磺酸阿帕替尼治疗非小细胞肺癌中的临床疗效预测意义[D]. 浙江大学, 2019.
20 李艳芳, 姜海英, 李 倩, 等. 阿帕替尼联合化疗一线治疗驱动基因阴性晚期非小细胞肺癌的临床研究[J]. 中华肿瘤杂志, 2019, 41(10): 775-781.
21 黄 海, 毕 锋. 阿帕替尼在恶性肿瘤治疗中的临床应用[J]. 国际肿瘤学杂志, 2019, 46(1): 45-48.
22 陈艳丽, 王媛媛, 张 勇, 等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
23 桂思吟. 青蒿琥酯调节肺癌患者细胞毒性T淋巴细胞CD39与PD-1分子表达及其抗肿瘤作用[D]. 安徽理工大学, 2019.
24 张韶岩, 李 文, 张永志, 等. 非小细胞肺癌患者外周血调节性T细胞表达及意义[J]. 中华实用诊断与治疗杂志, 2012, 26(7): 645-647.
25 聂 刚, 范志民. T细胞型细胞因子与非小细胞肺癌的相关性研究[J]. 中国医药, 2008, 3(7): 445-446.
26 Simon V, Christine KA, Véronique F, et al. C3 glomerulonephritis in a patient treated with anti PD-1 antibody[J]. European Journal of Cancer, 2019, 12(5): 2145-2150.
27 高 锋, 陈丽秀, 朱于娟, 等. CD73与调节性T细胞在非小细胞肺癌中的表达及其临床意义[J]. 临床肺科杂志, 2020, 25(6): 902-907.
28 奉 林. 晚期非小细胞肺癌患者外周血CD4+CD25+FOXP3+调节性T细胞的表达及临床意义[J]. 中国肿瘤临床与康复, 2016, 23(2): 134-137.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金资助项目(81460356)
通信作者: 王 旋,Email: 610004286@qq.com
更新日期/Last Update: 2021-10-20